칼라 바이오 (KALA) 주가

칼라 바이오(KALA)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.54 (-4.53%), 시가총액 $57.02M, 52주 범위 $0.08 ~ $19.63.

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

핵심 지표

• 현재가: $0.54 (-4.53%)
• 시가총액: $57.02M
• 52주 최저~최고: $0.08 ~ $19.63
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

칼라 바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

칼라 바이오 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (4.5 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 10.50
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문